10 Month Vision Update After Having Stem Cell Treatment – What Am I Seeing Now??
My GoFundMe http://bit.ly/visionbill2 Stem Cell Treatment For Optic Atrophy Subscribe https://www.youtube.com/channel/UCrdenPUR_-i7zi5UagHjXJQ?sub_confirmation=1 In this video I am going to give my status update after having a stem cell procedure don in South Florida. I took place in a clinical trial known as SCOTS (Stem Cell Ophthalmology Treatment Study). I did this procedure because I have optic atrophy. I am now legally blind due to this condition. This clinical trial is for people with a variety of eye conditions that can hopefully be helped by using the patients own bone marrow derived stem cells. Form the SCOTS clinical trial page: Conditions potentially eligible for the new study include retinal diseases such as age-related macular degeneration (AMD), myopic macular degeneration, hereditary retinopathies such as Retinitis Pigmentosa and Stargardts, as well as selected inflammatory, vascular and traumatic conditions. Optic nerve diseases considered eligible include glaucoma, ischemic optic neuropathy, optic atrophy, optic neuritis, LHON / Leber Hereditary Optic Neuropathy, NMO / Neuromyelitis Optica or Devic's Syndrome and some trauma. The study is focused on the ocular tissue that has sustained damage and its potential for improvement rather than a specific disease entity. For many patients with serious eye disease, going blind is a constant fear. The loss of vision experienced from retinal or optic nerve problems may be progressive with devastating impact on a person’s ability to live a full life. Treatment with Bone Marrow Derived Stem Cells may hold the key to reversing blindness and restoring vision. But the concern has been whether such stem cell treatments have enough published reports and studies to show effectiveness in a convincing way. MD Stem Cells hopes to help provide that evidence. MD Stem Cells has been named Collaborator for the new Stem Cell Ophthalmology Treatment Study, abbreviated as SCOTS. Dr. Steven Levy, President of MD Stem Cells, will function as Study Director for the clinical trial expected to continue through August 2017. The Retinal Associates of South Florida is the study Sponsor and Dr. Jeffrey Weiss, retinal surgeon and physician, is the Principle Investigator and provider of the ophthalmic stem cell treatments. SCOTS is being conducted in Florida.
My GoFundMe http://bit.ly/visionbill2 Stem Cell Treatment For Optic Atrophy Subscribe https://www.youtube.com/channel/UCrdenPUR_-i7zi5UagHjXJQ?sub_confirmation=1 In this video I am going to give my status update after having a stem cell procedure don in South Florida. I took place in a clinical trial known as SCOTS (Stem Cell Ophthalmology Treatment Study). I did this procedure because I have optic atrophy. I am now legally blind due to this condition. This clinical trial is for people with a variety of eye conditions that can hopefully be helped by using the patients own bone marrow derived stem cells. Form the SCOTS clinical trial page: Conditions potentially eligible for the new study include retinal diseases such as age-related macular degeneration (AMD), myopic macular degeneration, hereditary retinopathies such as Retinitis Pigmentosa and Stargardts, as well as selected inflammatory, vascular and traumatic conditions. Optic nerve diseases considered eligible include glaucoma, ischemic optic neuropathy, optic atrophy, optic neuritis, LHON / Leber Hereditary Optic Neuropathy, NMO / Neuromyelitis Optica or Devic's Syndrome and some trauma. The study is focused on the ocular tissue that has sustained damage and its potential for improvement rather than a specific disease entity. For many patients with serious eye disease, going blind is a constant fear. The loss of vision experienced from retinal or optic nerve problems may be progressive with devastating impact on a person’s ability to live a full life. Treatment with Bone Marrow Derived Stem Cells may hold the key to reversing blindness and restoring vision. But the concern has been whether such stem cell treatments have enough published reports and studies to show effectiveness in a convincing way. MD Stem Cells hopes to help provide that evidence. MD Stem Cells has been named Collaborator for the new Stem Cell Ophthalmology Treatment Study, abbreviated as SCOTS. Dr. Steven Levy, President of MD Stem Cells, will function as Study Director for the clinical trial expected to continue through August 2017. The Retinal Associates of South Florida is the study Sponsor and Dr. Jeffrey Weiss, retinal surgeon and physician, is the Principle Investigator and provider of the ophthalmic stem cell treatments. SCOTS is being conducted in Florida.